Pharmacokinetics of tacrolimus and mycophenolic acid are altered, but recover at different times during hepatic regeneration in rats.

Hepatic regeneration is very critical to the success of living donor liver transplantation, which allows a reduced size liver to grow in size to accommodate the requirements of both the donor and the recipient. The objectives of this study were to evaluate 1) the hepatic metabolism of the two immunosuppressive drugs, tacrolimus and mycophenolic acid (MPA), and 2) the pharmacokinetics of tacrolimus and mycophenolic acid at various time points after initiation of hepatic regeneration by partial hepatectomy in rats. The hepatic intrinsic clearance of tacrolimus was decreased to 70% and 51% of the control level at the 24th h and the 6th day, respectively, but returned to normal level by day 14. The total body clearance of tacrolimus was reduced transiently but recovered completely by day 18. The hepatic intrinsic clearance of MPA was decreased to 52% and 51% of that in control rats at the 24th h and the 6th day, respectively, but recovered to normal level by day 14. The total body clearance of MPA was reduced at the 24th h but recovered by day 6. The magnitude of reduction in the clearance of tacrolimus and MPA was much smaller than what was predicted from in vitro data. The elimination clearance of MPA glucuronide was also impaired during hepatic regeneration but recovered to normal level with time. In conclusion, the pharmacokinetics of tacrolimus and mycophenolic acid were altered during hepatic regeneration but recovered completely at different rates over time. Caution must be exercised in extrapolating in vitro data to in vivo conditions during hepatic regeneration.     

波依定与洛汀新治疗不同中医证型高血压疗效比较

目的:观察波依定与洛汀新对不同中医证型高血压的疗效是否具有中草药的某些特征,能否按中医辨证选择抗高血压药.方法:按照WHO的标准明确高血压诊断与分级,根据<中药新药临床研究指导原则>分为4型.216例患者随机分为两组,分别给予波依定与洛汀新治疗,疗程4周.分析对总体血压和不同证型血压的影响,以及对不同症状的疗效有无差异.结果:两种药物降低患者总体血压的幅度基本相同;但分层研究,对4种中医证型患者的血压的降低程度明显不同,洛汀新对肝火亢盛型血压降低幅度更明显,波依定对痰湿壅盛型比其它三型降压更好;对阴虚阳亢型和阴阳两虚型两组之间差异无显著性.对各种证型症状的改善作用也显示同样的结果.结论:抗高血压药对不同中医证型高血压的疗效不同,表明西药也同样具有中草药的某些特性,可以根据中医辨证选择抗高血压药.     

Solitary fibrous tumors of the pleura: clinical, radiological, surgical and pathological evaluation.

AIMS: To report a clinicopathological series of cases of solitary fibrous tumor of the pleura from Taiwan. METHODS: Clinical data was collected from a review of medical records and telephone interviewing for follow-up. RESULTS: Eight patients, three men and five women aging from 34 to 71 years, underwent tumor resection and were followed in a period from 7 months to 13.5 years. Six patients underwent standard thoracotomy and two had VATS for tumor excision. Tumors were pathologically benign in seven patients and malignant in one. Patients were all alive with no evidence of tumor recurrence at the time of this report. CONCLUSIONS: One should always consider SFTPs as potentially malignant tumors. Complete resection remains the mainstay of cure. Standard thoracotomy should always be considered when a high suspicion of malignancy is raised, whereas VATS may be a preferred approach for smaller tumors.     

AIF重组质粒的构建、表达和功能的研究

目的构建人凋亡诱导因子(AIF)基因功能片段的真核表达载体pcDNA3.1( )AIF,并初步研究AIF在细胞凋亡中的作用。方法从人细胞中提取总RNA,RTPCR扩增AIF基因片段;克隆到pMD18T载体上,通过酶切和测序进行鉴定;将AIF基因片段插入pcDNA3.1( ),构建真核表达载体;电转化淋巴母细胞Raji细胞,观察AIF的表达水平和功能。结果成熟AIF蛋白分子在真核细胞中表达,并转移到细胞核中,诱导Caspase非依赖性细胞凋亡。结论成功构建了pcDNA3.1( )AIF真核表达载体,AIF在Caspase非依赖性细胞凋亡中发挥重要作用。     

米团花色素的提取及其稳定性研究

米团花色素是云南省某些地区居民使用的一种传统黄色天然食用色素.本研究表明,米团花色素在433 nm和326 nm处分别有一个较强吸收峰.稳定性实验表明:该色素对酸、热、光、氧化剂过氧化氢(不加热)、常见金属离子、食盐及食糖等稳定,但在碱性条件或亚硫酸钠存在时不太稳定.此外,加入过氧化氢后加热也会引起其吸光值的显著改变.初步确定米团花色素主要为胺类物质.在正常加工条件下,是一种较理想的天然食用色素.     

九节茶资源调查与开发前景

通过调查,华南部分地区,包括广东、广西及江西等地的九节茶资源非常丰富,极具开发前景.     

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

BackgroundHyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC), could be beneficial to both hyperphosphatemia and anemia.MethodsRelevant literature from PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials (CCRCT) and MEDLINE databases were searched up to 21 February 2022, in order to conduct a meta-analysis to investigate the efficacy, safety and economic benefits of ferric citrate treatment in CKD patients with hyperphosphatemia and anemia. The meta-analysis was conducted independently by two reviewers using the RevMan software (version 5.3).ResultsIn total, this study included 16 randomized clinical trials (RCT) involving 1754 participants. The meta-analysis showed that ferric citrate could significantly reduce the serum phosphorus in CKD patients compared to the placebo control groups (MD −1.76 mg/dL, 95% CI (−2.78, −0.75); p = 0.0007). In contrast, the difference between ferric citrate treatment and active controls, such as non-iron-based phosphate binders, sevelamer, calcium carbonate, lanthanum carbonate and sodium ferrous citrate, was not statistically significant (MD − 0.09 mg/dL, 95% CI (−0.35, 0.17); p = 0.51). However, ferric citrate could effectively improve hemoglobin levels when compared to the active drug (MD 0.43 g/dL, 95% CI (0.04, 0.82); p = 0.03) and placebo groups (MD 0.39 g/dL, 95% CI (0.04, 0.73); p = 0.03). According to eight studies, ferric citrate was found to be cost-effective treatment in comparison to control drugs. Most of the adverse events (AE) following ferric citrate treatment were mild at most.ConclusionCollectively, our review suggests that iron-based phosphate binder, ferric citrate is an effective and safe treatment option for CKD patients with hyperphosphatemia and anemia. More importantly, this alternative treatment may also less expensive. Nevertheless, more scientific studies are warranted to validate our findings.     

基于TGF-β/smad信号通路探讨七方胃痛颗粒对人胃腺癌AGS细胞上皮间质转化过程的影响＊

目的 探究七方胃痛颗粒对转化生长因子-β1（TGF-β1）诱导人胃腺癌细胞AGS上皮间质转化（Epithelial-mesenchymal transition， EMT）过程的影响及其潜在分子机制。方法 为了探究七方胃痛颗粒对TGF-β1处理的AGS细胞增殖、迁移和侵袭的影响，实验分为四组：AGS细胞对照组，EMT空白模型组，中药血清组，TGF-β/smad通路抑制剂组，分别利用CCK8、细胞划痕实验和Transwell实验检测细胞增殖、迁移和侵袭能力。此外，通过免疫荧光检测EMT过程中相关蛋白（E-cadherin、N-cadherin、14-3-3ζ、Smad2和p-Smad2/3）的表达水平。结果 与AGS细胞对照组相比，TGF-β1诱导EMT过程，显著促进AGS细胞增殖、迁移和侵袭，下调了E-cadherin的表达，上调了N-cadherin、14-3-3ζ、Smad2和p-Smad2/3的表达；与EMT空白模型组相比，中药血清组、TGF-β/smad通路抑制剂组显著抑制了细胞增殖、迁移和侵袭，上调了E-cadherin的表达，降低了N-cadherin、14-3-3ζ、Smad2和p-Smad2/3的表达。结论 七方胃痛颗粒通过调控TGF-β/smad信号通路从而抑制人胃腺癌AGS细胞的EMT过程。     

妊娠妇女血清25-羟维生素D水平及其与血脂相关性研究

目的观察妊娠中晚期妇女血清维生素D水平与血脂的相关性。方法 353名孕妇,孕期12~36周时,空腹采血检测25-羟维生素D[25-(OH)D]、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)。按照血清25-(OH)D水平分为维生素D缺乏(≤20ng/mL)、维生素D不足(21~29ng/mL)及维生素D正常(≥30ng/mL)三组,比较组间总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白的差异,分析血脂各指标与血清25-(OH)D水平的相关性。结果在353中晚期妊娠妇女中,221例(62.61%)为维生素D缺乏,89例(25.21%)为维生素D不足,43例(12.18%)为维生素D正常,维生素D水平级别与总胆固醇、甘油三酯、低密度脂蛋白为正相关(相关系数rs分别为0.075、0.082、0.071),与高密度脂蛋白为负相关(相关系数rs=-0.0209),差异无统计学意义(P>0.05)。结论维生素D不足和缺乏在妊娠中晚期妇女中普遍存在,但与血脂无相关性。     

中西医结合治疗216例哮喘儿童的临床效果与生活质量评价

目的对中西医结合治疗支气管哮喘（简称哮喘）患儿临床疗效与生活质量进行评价,并以单纯西医治疗为对照,探讨哮喘中西医结合治疗的优势。方法在GINA方案的基础上将444例哮喘患儿随机分为观察组和对照组,观察组加用中药汤剂及穴位贴敷,总疗程2年,观察两组治疗前后临床疗效指标及生活质量变化。结果在改善肺功能、减少呼吸道感染次数方面,两组比较差异有统计学意义（P〈0．01）,观察组优于对照组。观察组在住院率、急诊率、缺课率（节）、心理障碍率、运动受限率等方面优于对照组,P〈0．01,提高哮喘患儿生活质量方面优于对照组。结论中西医结合治疗小儿哮喘能显著改善哮喘患儿临床症状及肺功能,具有较好的远期疗效,并能显著提高哮喘患儿的生活质量。